Publication | Closed Access

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

First-line TherapyBreast OncologyProspective Biomarker EvaluationMedicinePharmacologyClinical TrialsPaclitaxel Versus PlaceboBreast CancerPharmacotherapyCancer TreatmentOncology